Attività di valutazione della ricerca

Size: px
Start display at page:

Download "Attività di valutazione della ricerca"

Transcription

1 Pier-Luigi Lollini Pier-Luigi Lollini è Professore di Patologia Generale all'università di Bologna, dove insegna Oncologia Molecolare e Patologia Genetica. Nato a Bologna nel 1956, si è laureato in Scienze Biologiche nel 1980 a Bologna e nel 1987 ha conseguito il Dottorato di Ricerca in Oncologia. Insegna all'università di Bologna dal Dal 2004 al 2007 è stato Direttore del Centro Interdipartimentale di Ricerche sul Cancro Giorgio Prodi dell Università di Bologna, in precedenza è stato Direttore dell'istituto di Cancerologia e membro della Commissione per la valutazione dei finanziamenti alla ricerca medica. È membro del Comitato Tecnico-Scientifico nazionale e del Comitato Emilia Romagna dell'associazione Italiana per la Ricerca sul Cancro (AIRC). È Editor di Rendiconti Lincei - Scienze fisiche e naturali, rivista scientifica della Accademia dei Lincei. Dal 2001 al 2005 è stato Consigliere della Società Italiana di Cancerologia (SIC), Associate Editor di Tumori, organo ufficiale della SIC, ed Editor del sito Web della SIC, Con un gruppo di ricercatori coetanei (Patrizia Nanni, Carla De Giovanni, Giordano Nicoletti) ha dato vita all'inizio degli anni 80 al Laboratorio di Immunologia e Biologia delle Metastasi, le cui principali linee di ricerca riguardano l immunologia, l immunoterapia e l immunoprevenzione dei tumori, la terapia genica, i meccanismi della diffusione metastatica, la biologia cellulare e molecolare dei tumori muscolo-scheletrici umani. I risultati sono pubblicati in oltre 170 lavori sulle principali riviste scientifiche internazionali. Pier-Luigi Lollini, Laboratorio di Immunologia e Biologia delle Metastasi, Viale Filopanti 22, Bologna. Tel ; fax ; sito web: 1

2 Attività di valutazione della ricerca Membro del Comitato Tecnico-Scientifico (CTS) dell Associazione Italiana per la Ricerca sul Cancro (AIRC) dal 2000 al 2002 e dal 2006 ad oggi. Il CTS coordina la valutazione dei progetti di ricerca presentati ad AIRC (alcune centinaia di progetti ogni anno, per un budget di circa 50 milioni di Euro/anno). Membro della Commissione Scientifica del Comitato 06 (Scienze Mediche) per la ripartizione dei Fondi Ricerca Scientifica (60%) dell'università di Bologna. Trienni 1998/2000 e 2001/2003, circa 150 progetti valutati/anno. Valutazione di progetti di ricerca applicata per le Regioni Piemonte ( ) e Toscana Valutazione di proposte di progetti di rilevante interesse nazionale (PRIN) presentati al Ministro dell Università e della Ricerca (MIUR) Valutazione ad hoc di progetti di ricerca per United States-Israeli Binational Science Foundation, German-Israeli Foundation for Scientific Research & Development, Austrian Science Fund, Israel Science Foundation, Swiss National Science Foundation. Membro della Commissione di valutazione dell iniziativa BioInItaly 2010, promossa dall Associazione nazionale per lo sviluppo delle biotecnologie (Assobiotec). Revisore (referee) di manoscritti per le riviste Nature Reviews Cancer, Journal of Experimental Medicine, Journal of Immunology, Journal of Translational Medicine, Nature Biotechnology, Cancer Research, Cancer Cell, Transgenic Research, Cell Proliferation, Journal of Pathlogy, Virchows Archiv, International Journal of Cancer, International Journal of Radiation Biology. European Journal of Cancer, Cinical Cancer Research, Human Gene Therapy. Iscritto all Albo degli Esperti FAR (Fondo Agevolazioni alla Ricerca) del MIUR, e precedentemente all'elenco degli Esperti dello stesso Ministero. Pubblicazioni in extenso (ordine cronologico inverso) P.-L. Lollini, F. Cavallo, C. De Giovanni & P. Nanni. Preclinical vaccines against mammary carcinoma. Exp. Rev. Vaccines, in press, Calabrese, Iommarini, Kurelac, Calvaruso, Capristo, Lollini, Nanni, Bergamini, Nicoletti, De Giovanni, Ghelli, Giorgio, Caratozzolo, Marzano, Manzari, Betts, Carelli, Ceccarelli, Attimonelli, Romeo, Fato, Rugolo, Tullo, Gasparre, & Porcelli. Respiratory complex I is essential to induce a Warburg profile in mitochondriadefective tumor cells. Cancer & Metabolism, 1: 11, in press, P. Nanni, V. Gatta, L. Menotti, C. De Giovanni, M. Ianzano, A. Palladini, V. Grosso, M. Dall Ora, S. Croci, G. Nicoletti, L. Landuzzi, M. Iezzi, G. Campadelli- Fiume & P.-L. Lollini. Preclinical therapy of disseminated HER-2+ ovarian and 2

3 breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathogens, 9(1): e , C. Zucchini, M.C. Manara, R.S. Pinca, P. De Sanctis, C. Guerzoni, M. Sciandra, P.- L. Lollini, G. Cenacchi, P. Picci, L. Valvassori, & K. Scotlandi. CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene, in press, Published online May 6, M.L. Ianzano, S. Croci, G. Nicoletti, A. Palladini, L. Landuzzi, V. Grosso, D. Ranieri, M. Dall Ora, I. Santeramo, M. Urbini, C. De Giovanni, P.-L. Lollini & P. Nanni. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. Oncotarget, in press, Published online August 6, P.-L. Lollini, C. De Giovanni & P. Nanni. Preclinical HER-2 vaccines: from rodent to human HER-2. Front. Oncol., 3: 151, L. Menotti, G. Campadelli-Fiume, P. Nanni, P.-L. Lollini & C. De Giovanni. The molecular basis of herpesviruses as oncolytic agents. Curr. Pharm. Biotechnol., 13: , Published online July 8, F. Castiglione, P.-L. Lollini, S. Motta, A. Palladini, F. Pappalardo & M. Pennisi. Computational models as novel tools for cancer vaccines. In: A. d'onofrio, P. Cerrai, A. Gandolfi (Eds.), New challenges for cancer systems biomedicine. Springer-Verlag, Milano, ISBN pp C. De Giovanni, G. Nicoletti, L. Landuzzi, F. Romani, S. Croci, A. Palladini, A. Murgo, A. Antognoli, M.L. Ianzano, V. Stivani, V. Grosso, M. Iezzi, L. Stramucci, E. Barbieri, R.M. Lemoli, P. Nanni & P.-L. Lollini. Human responses against HER- 2-positive cancer cells in Human Immune System (HIS)-engrafted mice. Br. J. Cancer, 107: , P. Nanni, G. Nicoletti, A. Palladini, S. Croci, A. Murgo, M.L. Ianzano, V. Grosso, V. Stivani, A. Antognoli, A. Lamolinara, L. Landuzzi, E. Di Tomaso, M. Iezzi, C. De Giovanni, & P.-L. Lollini. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS One, 7(6): e39626, doi: /journal.pone M. Iezzi, E. Quaglino, A. Amici, P.-L. Lollini, G. Forni & F. Cavallo. DNA vaccination against oncoantigens. A promise. OncoImmunology, 1: , G. Campadelli-Fiume, L. Menotti, G. Zhou, C. De Giovanni, P. Nanni & P.-L. Lollini. Herpesviruses as oncolytic agents. In: J.A. Blaho & J.D. Baines (Eds.). From the hallowed halls of herpesvirology - A tribute to Bernard Roizman. World Scientific Publishing, Singapore, ISBN Pages P.-L. Lollini, G. Nicoletti, L. Landuzzi, F. Cavallo, G. Forni, C. De Giovanni & P. Nanni. Vaccines and other immunological approaches for cancer immunoprevention. Curr. Drug Targets, 12: , Published online Dec 15, M. Maio, H.J.M. Nicolay, P.A. Ascierto, F. Belardelli, R. Camerini, M.P. Colombo, P. Queirolo, R. Ridolfi, V. Russo, E. Fonsatti, NIBIT (P.-L. Lollini included in NIBIT co-authors) & G. Parmiani. Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7 9, Cancer Immunol. Immunother., 60: , G. Gasparre, I. Kurelac, M. Capristo, L. Iommarini, A. Ghelli, C. Ceccarelli, G. Nicoletti, P. Nanni, C. De Giovanni, K. Scotlandi, C.M. Betts, V. Carelli, P.-L. Lollini, G. Romeo, M. Rugolo & A.M. Porcelli. A mutation threshold distinguishes the anti-tumorigenic effects of the mitochondrial gene MTND1, an oncojanus function. Cancer Res., 71: ,

4 L. Landuzzi, A. Antognoli, G. Nicoletti, S. Croci, A. Palladini, M.L. Ianzano, A. Murgo, V. Stivani, V. Grosso, P. Nanni, C. De Giovanni & P.-L. Lollini. HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. Vaccine, 29: , P.-L. Lollini, P. Nanni & C. De Giovanni. Immunotherapy. In: D. Lyden, D.R. Welch, B. Psaila (Eds.), Cancer metastasis: Biologic basis and therapeutics. Cambridge University Press, ISBN: Pages T. Mueck, F. Berger, I. Buechsler, R.S. Valchanova, L. Landuzzi, P.-L. Lollini, K. Klingel & B. Munz. TRAF6 regulates proliferation and differentiation of skeletal myoblasts. Differentiation, 81: , E. Bolli, E. Quaglino, M. Arigoni, P.-L. Lollini, R. Calogero, G. Forni & F. Cavallo. Oncoantigens for an immune prevention of cancer. Am. J. Cancer Res., 1: , Published online Dec 10, F. Cavallo, C. De Giovanni, P. Nanni, G. Forni & P.-L. Lollini. 2011: The immune hallmarks of cancer. Cancer Immunol. Immunother., 60: , 2011 M. Pasello, M.C. Manara, F. Michelacci, M. Fanelli, C.M. Hattinger, G. Nicoletti, L. Landuzzi, P.-L. Lollini, A. Caccuri, P. Picci, K. Scotlandi & M. Serra. Targeting glutathione-s transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Anal. Cell. Pathol., 34: , C. Garofalo, M. C. Manara, G. Nicoletti, M.T. Marino, P.-L. Lollini, A. Astolfi, G. Pandini, J.A. López-Guerrero, K.L. Schaefer, A. Belfiore, P. Picci & K. Scotlandi. Efficacy of and resistance to anti-igf-1r therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 30: , G. Campadelli-Fiume, C. De Giovanni, V. Gatta, P. Nanni, P.-L. Lollini & L. Menotti. Rethinking herpes simplex virus: the way to oncolytic agents. Rev. Med. Virol., 21: , G. Forni & P.-L. Lollini. Vaccini antitumorali. 2 Supplemento Enciclopedico (Aggiornamento , H-Z) de "La Piccola Treccani", Istituto della Enciclopedia Italiana Treccani, Roma, P. Nanni, G. Nicoletti, L. Landuzzi, S. Croci, A. Murgo, A. Palladini, A. Antognoli, M.L. Ianzano, V. Stivani, V. Grosso, S.-M. Maira, C. García-Echeverría, K. Scotlandi, C. De Giovanni, & P.-L. Lollini. High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic drug therapy. Eur. J. Cancer, 46: , M.A. Pantaleo, E. Mishani, C. Nanni, L. Landuzzi, S. Boschi, G. Nicoletti, S. Dissoki, P. Paterini, P.P. Piccaluga, F. Lodi, P.-L. Lollini, S. Fanti & G. Biasco. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol. Imaging Biol., 12: , D. Zambelli, M. Zuntini, F. Nardi, M.C. Manara, M. Serra, L. Landuzzi, P.-L. Lollini, S. Ferrari, M. Alberghini, A. Llombart-Bosch, E. Piccolo, S. Iacobelli, P. Picci & K. Scotlandi. Biological indicators of prognosis in Ewing s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int. J. Cancer, 126: 41-52, Published online June 19, M.A. Pantaleo, G. Nicoletti, C. Nanni, C. Gnocchi, L. Landuzzi, C. Quarta, S. Boschi, M. Nannini, M. Di Battista, P. Castellucci, S. Fanti, P.-L. Lollini, E. Bellan, M. Castelli, D. Rubello & G. Biasco. Preclinical evaluation of KIT/PDGFRA and mtor inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J. Exp Clin. Cancer Res., 29: 173,

5 E. Quaglino, C. Mastini, A. Amici, C. Marchini, M. Iezzi, S. Lanzardo, C. De Giovanni, M. Montani, P.-L. Lollini, G. Masucci, G. Forni & F. Cavallo. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res., 70: , F. Pappalardo, M. Pennisi, A. Cincotti, F. Chiacchio, S. Motta & P.-L. Lollini. Cancer immunoprevention: What can we learn from in silico models? In: D.-S. Huang, M. McGinnity, L. Heutte, X.-P. Zhang (Eds.), Advanced intelligent computing theories and applications, (Communications in computer and information science Vol. 93), p , Springer, Berlin-Heidelberg, S. Croci, C.V. Recktenwald, R. Lichtenfels, G. Nicoletti, S.P. Dressler, C. De Giovanni, A. Astolfi, A. Palladini, K. Shin-ya, L. Landuzzi, P. Nanni, P.-L. Lollini & B. Seliger. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Proteomics, 10: , Palladini, G. Nicoletti, F. Pappalardo, A. Murgo, V. Grosso, V. Stivani, M. Ianzano, A. Antognoli, S. Croci, L. Landuzzi, C. De Giovanni, S. Motta & P.-L. Lollini. In silico modeling and in vivo efficacy of cancer preventive vaccinations. Cancer Res., 70: , M Halling-Brown,F Pappalardo,N Rapin,P Zhang,D Alemani,A Emerson,F Castiglione,P Duroux,M Pennisi,O Miotto,D Churchill,E Rossi,D Moss,C Sansom,M Bernaschi,MP Lefranc,S Brunak,O Lund,S Motta,PL Lollini,A Murgo,A Palladini,K Basford,V Brusic,AJ Shepherd. ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale. Phil. Trans. R. Soc. A, 368: , P.-L. Lollini, G. Nicoletti, L. Landuzzi, C. De Giovanni & P. Nanni. Immunoprevention and immunotherapy of mammary carcinoma. Breast J., 16 S1: 39-41, M. Pennisi, F. Pappalardo, A. Palladini, G. Nicoletti, P. Nanni, P.-L. Lollini & S. Motta. Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics, 11 (Suppl. 7): S13, M. Maio, H.J. Nicolay, P.A. Ascierto, F. Belardelli, R. Camerini, M.P. Colombo, P. Queirolo, R. Ridolfi, V. Russo, E. Fonsatti, G. Parmiani & NIBIT. (P.-L. Lollini included in NIBIT co-authors). Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October Cancer Immunol. Immunother., 59: , (published online Mar. 28, 2009) Astolfi, P.-L. Lollini, S. Motta, F. Pappalardo. Current issues in tumor immunology. Curr. Bioinform, 5: , M.C. Manara, G. Nicoletti, D. Zambelli, S. Ventura, C. Guerzoni, L. Landuzzi, P.- L. Lollini, S.-M. Maira, C. Garcia-Echeverria, M. Mercuri, P. Picci & K. Scotlandi. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin. Cancer Res., 16: F. Pappalardo, M.-P. Lefranc, P.-L. Lollini & S. Motta. A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY. Immunome Res., 6(1): 1-14, G. Nicoletti, A. Palladini, A. Murgo, A. Antognoli, S. Croci, F. Pappalardo, S. Motta & P.-L. Lollini. Translational immunomics of cancer prevention. In A. Falus (Ed.), Clinical applications of immunomics, Springer, New York, 2009, pp ISBN: M.A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini & G. Biasco. Experimental results and related 5

6 clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann. Oncol., 20: , Published online October 7, F Pappalardo, M Halling-Brown, N Rapin, P Zhang, D Alemani, A Emerson, P Paci, P Duroux, M Pennisi, A Palladini, O Miotto, D Churchill, E. Rossi, A Shepherd, D Moss, F Castiglione, M Bernaschi, M Lefranc, S Brunak, S Motta, P Lollini, K Basford, V Brusic. ImmunoGrid, an integrative environment for largescale simulation of the immune system for vaccine discovery, design, and optimization. Brief. Bioinform., 10: , De Giovanni, G. Nicoletti, L. Landuzzi, S. Croci, A. Palladini, A. Antognoli, A. Murgo, M.L. Ianzano, V. Grosso, V. Stivani, M. Iezzi, P. Musiani, P. Nanni & P.-L. Lollini. Tamoxifen combined to anti-her-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. Vaccine, 27: , P. Nanni, G. Nicoletti, A. Palladini, A. Astolfi, P. Rinella, S. Croci, L. Landuzzi, G. Monduzzi, V. Stivani, A. Antognoli, A. Murgo, M.L. Ianzano, C. De Giovanni & P.-L. Lollini. Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Mol. Cancer Ther., 8: , De Giovanni, G. Nicoletti, A. Palladini, S. Croci, L. Landuzzi, A. Antognoli, A. Murgo, A. Astolfi, S. Ferrini, M. Fabbi, A.M. Orengo, A. Amici, M. L. Penichet, L. Aurisicchio, M. Iezzi, P. Musiani, P. Nanni & P.-L. Lollini. A multi-dna preventive vaccine for p53/neu driven cancer syndrome. Hum. Gene Ther., 20: , M.A. Pantaleo, L. Landuzzi, G. Nicoletti, C. Nanni, S. Boschi, G. Piazzi, D. Santini, M. Di Battista, P. Castellucci, F. Lodi, S. Fanti, P.-L. Lollini & G. Biasco. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the Gastrointestinal Stromal Tumors (GISTs) model. Clin. Exp. Med, 9: , M.A. Pantaleo, M. Nannini, S. Fanti, S. Boschi, P.-L. Lollini & G. Biasco. Molecular imaging of EGFr: it s time to go beyond the receptor expression. J. Nucl. Med, 50: , L. Menotti, G. Nicoletti, V. Gatta, S. Croci, L. Landuzzi, C. De Giovanni, P. Nanni, P.-L. Lollini & G. Campadelli-Fiume. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc. Natl. Acad. Sci. USA, 106: , P.-L. Lollini, L. Menotti, C. De Giovanni, G. Campadelli-Fiume & P. Nanni. Oncolytic herpes virus retargeted to HER-2. Cell Cycle, 8: , De Giovanni, L. Landuzzi, G. Nicoletti, P.-L. Lollini & P. Nanni. Molecular and cellular biology of rhabdomyosarcoma. Future Oncol., 5: , P.-L. Lollini & P. Nanni. Immunoprevention of cancer. In: M. Schwab (Ed.), Encyclopedia of Cancer 2nd ed. Springer, Heidelberg, 2008, pp ISBN: S. Motta, F. Pappalardo & P.-L. Lollini. Modeling vaccine's protocols. In: R.J. Hosking, E. Venturino (Eds.), Aspects of mathematical modeling: Applications in science, medicine, economics and management. Birkhauser, Basel, ISBN: S. Ehlers, T. Mueck, S. Adams, L. Landuzzi, P.-L. Lollini & B. Munz. RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. Eur. J. Cell. Biol., 87: , P.-L. Lollini, A. Palladini, F. Pappalardo & S. Motta. Predictive models in tumor immunology. In: N. Bellomo, M. Chaplain, E. De Angelis (Eds.), Selected topics in 6

7 cancer modeling: Genesis, evolution, immune competion, and therapy. Birkhauser, Boston, 2008, pp ISBN: M.A. Pantaleo, S. Fanti, P.-L. Lollini, S. Boschi & G. Biasco. PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment? Eur. J. Nucl. Med. Mol. Imaging, 34: , S. Croci, G. Nicoletti, L. Landuzzi, A. Palladini, F. Chiarini, P. Nanni, P.-L. Lollini & C. De Giovanni. Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. Oncology Reports, 18: , De Giovanni, S. Croci, G. Nicoletti, L. Landuzzi, A. Palladini, T. Pannellini, L. Borgia, M. Iezzi, E. Di Carlo, A.M. Orengo, R.C. Kennedy, P.-L. Lollini, P. Nanni & P. Musiani. Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. Int. J. Cancer, 121: 88-94, Pappalardo, S. Motta, P.-L. Lollini, E. Mastriani & M. Pennisi. Towards a personalized schedule with triplex vaccine. Lecture Notes in Computer Science, 4578: , K. Scotlandi, M. Zuntini, M.C. Manara, M. Sciandra, A. Rocchi, S. Benini, G. Nicoletti, G. Bernard, P. Nanni, P.-L. Lollini, A. Bernard & P. Picci. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-src kinase activity. Oncogene, 26: , P. Nanni, G. Nicoletti, A. Palladini, S. Croci, A. Murgo, A. Antognoli, L. Landuzzi, M. Fabbi, S. Ferrini, P. Musiani, M. Iezzi, C. De Giovanni & P.-L. Lollini. Antimetastatic activity of a preventive cancer vaccine. Cancer Res., 67: , Pappalardo, S. Motta, P.-L. Lollini & E. Mastriani. Analysis of vaccine s schedules using models. Cell. Immunol., 244: , Published online 16 April M.C. Manara, L. Landuzzi, P. Nanni, G. Nicoletti, D. Zambelli, P.L. Lollini, C. Nanni, F. Hofmann, C. García-Echeverría, P. Picci & K. Scotlandi. Preclinical in vivo study of new insulin-like growth factor-i receptor-specific inhibitor in Ewing s sarcoma. Clin. Cancer Res., 13: , S. Croci, L. Landuzzi, G. Nicoletti, A. Palladini, A. Antognoli, C. De Giovanni, P. Nanni, & P.-L. Lollini. Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. Pathol. Oncol. Res., 13: , P.-L. Lollini. Immunologia dei tumori. In C. Caruso, F. Licastro (Eds.), Compendio di Patologia Generale, Casa Editrice Ambrosiana, Milano, 2007, pp ISBN: Pappalardo, E. Mastriani, P.-L. Lollini & S. Motta. Genetic algorithm against cancer. Lecture Notes in Computer Science, 3849: , Palladini, A. Astolfi, S. Croci, C. De Giovanni, G. Nicoletti, A. Rosolen, F. Sartori, P.-L. Lollini, L. Landuzzi & P. Nanni. Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. Eur. J Cancer, 42: , K. Scotlandi, S. Perdichizzi, G. Bernard, G. Nicoletti, P. Nanni, P.-L. Lollini, A. Curti, M. C. Manara, S. Benini, A. Bernard & P. Picci. Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing s sarcoma. Eur. J. Cancer, 42, 91-96, Available online 2 December M.C. Manara, G. Bernard, P.-L. Lollini, P. Nanni, M. Zuntini, L. Landuzzi, S. Benini, G. Lattanzi, M. Sciandra, M. Serra, M.P. Colombo, A. Bernard, P. Picci & 7

8 K. Scotlandi. CD99 acts as an oncosuppressor in osteosarcoma. Mol. Biol. Cell, 17: , P. Nanni, C. De Giovanni & P.-L. Lollini. Cancer biology, what we know and what we don't know. In G. Biasco, S. Tanneberger (Eds.), Cancer medicine at the dawn of the 21st century: The view from Bologna, Bononia University Press, 2006, pp ISBN: X T. Pannellini, M. Spadaro, E. Di Carlo, E. Ambrosino, M. Iezzi, A. Amici, P.-L. Lollini, G. Forni, F. Cavallo & P. Musiani. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant negative p53 makes their growth independent of HER-2/neu expression. J. Immunol., 176: , P.-L. Lollini, S. Motta & F. Pappalardo. Modeling tumor immunology. Math. Mod. Meth. Appl. Sci., 16: , P.-L. Lollini, S. Motta & F. Pappalardo. Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator. BMC Bioinformatics, 7: 352 (1-9), F. Pappalardo, P.-L. Lollini, S. Motta & E. Mastriani. Model deconstruction of an immunoprevention vaccine. Lecture Notes in Computer Science, 4222: , P.-L. Lollini, F. Cavallo, P. Nanni & G. Forni. Vaccines for tumour prevention. Nat. Rev. Cancer, 6: , S. Motta, F. Castiglione, P.-L. Lollini & F. Pappalardo. Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Res., 1: 5 (pp 1-18), Published online 7 Oct Cuadros, A.L. Dominguez, P.-L. Lollini, M. Croft, R.S. Mittler, P. Borgstrom & J. Lustgarten. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-ox40 and anti-4-1bb monoclonal antibodies induce a T cell mediated protective immunity in Her-2/neu transgenic mice. Int. J. Cancer, 116: , Published online 26 Apr Astolfi, S. Rolla, P. Nanni, E. Quaglino, C. De Giovanni, M. Iezzi, P. Musiani, G. Forni, P.-L. Lollini, F. Cavallo & R. Calogero. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: A microarray scenario. Cancer Immunol. Immunother., 54: P.-L. Lollini, C. De Giovanni, T. Pannellini, F. Cavallo, G. Forni & P. Nanni. Cancer immunoprevention. Future Oncol., 1: 57-66, M. Spadaro, E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W.Z. Wei, P. Musiani, P.-L. Lollini, F. Cavallo & G. Forni. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant IL-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res., 11: , Astolfi, L. Landuzzi, G. Nicoletti, C. De Giovanni, S. Croci, A. Palladini, S. Ferrini, M. Iezzi, P. Musiani, F. Cavallo, G. Forni, P. Nanni & P.-L. Lollini. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am. J. Pathol., 166: , P.-L. Lollini. Commentary on "High throughput views of cancer immune responsiveness", by E. Wang et al. Enhancer, 3: 20, K. Scotlandi, M.C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, C. García-Echeverría, F. Hofmann & P. Picci. Anti-tumor activity of the insulin-like growth factor-i receptor (IGF-IR) kinase 8

9 inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res., 65: , F. Casadio, S. Croci, A. D'Errico Grigioni, B. Corti, W.F. Grigioni, L. Landuzzi & P.-L. Lollini. Toward the definition of immunosuppressive regimens with antitumor activity. Transpl. Proc., 37: P.-L. Lollini, G. Nicoletti, L. Landuzzi, C. De Giovanni & P. Nanni. New target antigens for cancer immunoprevention. Curr. Cancer Drug Targets, 5: , F. Pappalardo, P.-L. Lollini, F. Castiglione & S. Motta. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics, 21: , S. Croci, PL. Strippoli, L. Bonsi, G.P. Bagnara, G. Guizzunti, R. Sartini, R. Tonelli, C. Messina, L. Pierdomenico & P.L. Lollini. Expression of T cell receptor alpha gene (TCRA) in human rhabdomyosarcoma and other musculo-skeletal sarcomas. Gene, 353: 16-22, M. Lo Iacono, F. Cavallo, E. Quaglino, S. Rolla, M. Iezzi, S.M. Pupa, C. De Giovanni, P.-L. Lollini, P. Musiani, G. Forni & R.A. Calogero. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. Int. J. Immunopathol. Pharmacol., 18: , P.-L. Lollini. Immune response to tumor. In: H.-W. Vohr (ed.), Encyclopedic reference of immunotoxicology, Springer, Heidelberg, pp F. Cavallo, A. Astolfi, M. Iezzi, F. Cordero, P.-L. Lollini, G. Forni & R. Calogero. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics, 6 (Suppl. 4): S7, Published online 1 December P.-L. Lollini Terapia genica. In G. Cantelli Forti, P. Hrelia (Eds.), "Le biotecnologie e la qualità della vita", Patron Editore, Bologna, 2005, pp ISBN E. Quaglino, S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P.-L. Lollini, S. Lanzardo, G. Forni, R. Sanges, S. Crispi, P. De Luca, R. Calogero, & F. Cavallo. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest., 113: , S. Tanzarella, I. Lionello, B. Valentinis, V. Russo, P.-L. Lollini & C. Traversari. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies. Cancer Immunol. Immunother., 53: , De Giovanni, L. Landuzzi, G. Nicoletti, A. Astolfi, S. Croci, M. Micaroni, P. Nanni & P.-L. Lollini. APC10.1: an Apc Min/+ intestinal cell line with retention of heterozygosity. Int. J. Cancer, 109: , S. Croci, L. Landuzzi, A. Astolfi, G. Nicoletti, A. Rosolen, F. Sartori, M.Y. Follo, N. Oliver, C. De Giovanni, P. Nanni & P.-L. Lollini. Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res., 64: , De Giovanni, G. Nicoletti, L. Landuzzi, A. Astolfi, S. Croci, A. Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, P. Musiani, F. Cavallo, P. Nanni & P.-L. Lollini. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine. Cancer Res., 64: ,

10 P. Nanni, L. Landuzzi, G. Nicoletti, C. De Giovanni, I. Rossi, S. Croci, A. Astolfi, M. Iezzi, E. Di Carlo, P. Musiani, G. Forni & P.-L. Lollini. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J. Immunol., 173: , S. Croci, G. Nicoletti, L. Landuzzi, C. De Giovanni, A. Astolfi, C. Marini, E. Di Carlo, P. Musiani, G. Forni, P. Nanni & P.-L. Lollini. Immunological prevention of a multigene cancer syndrome. Cancer Res., 64: , R. Giavazzi, M. Aglietta, A. Astolfi, A. Falanga, A. Fusco, R. Labianca, P.-L. Lollini, C. Lombardo, P.G. Natali, M.A. Pierotti, M. Presta, M. Santoro, G. Taraboletti, G. Zupi & G. Vecchio. Meeting report - 45th annual meeting of the Italian Cancer Society. Tumori, 90: , Quaglino, M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S.M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, P.-L. Lollini, P. Musiani, G. Forni & F. Cavallo. Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER- 2/neu transgenic mice. Cancer Res., 64: , P. Nanni, G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, M. Iezzi, C. Ricci, A. Astolfi, S. Croci, F. Marangoni, P. Musiani, G. Forni & P.-L. Lollini. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int. J. Cancer, 105: , P.-L. Lollini & G. Forni. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol., 24: 62-66, Curcio, E. Di Carlo, R. Clynes, M.J. Smyth, K. Boggio, E. Quaglino, M. Spadaro, M.P. Colombo, A. Amici, P.-L. Lollini, P. Musiani & G. Forni. Nonredundant roles of antibody, cytokines and perforin in the eradication of established Her-2/neu carcinomas. J. Clin. Invest., 111: , K. Scotlandi, M.C. Manara, R. Strammiello, L. Landuzzi, S. Benini, S. Perdichizzi, M. Serra, A. Astolfi, G. Nicoletti, P.-L. Lollini, F. Bertoni, P. Nanni & P. Picci. c-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J. Clin. Oncol., 21: , P. Cappello, F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P.-L. Lollini, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli & G. Forni. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res., 63: , Rosato, S. Dalla Santa, A. Zoso, S. Giacomelli, G. Milan, B. Macino, V. Tosello, P. Dellabona, P.-L. Lollini, C. De Giovanni & P. Zanovello. The cytotoxic T- lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res., 63: , P. Nanni, G. Nicoletti, C. De Giovanni, S. Croci, A. Astolfi, L. Landuzzi, E. Di Carlo, M. Iezzi, P. Musiani & P.-L. Lollini. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res., 63: , Forni, C. Curcio, M. Spadaro, J. Iliffe, E. Quaglino, E. Di Carlo, P. Musiani & P.-L. Lollini. Immunization in tumor prevention. Int. Immunopharmacol., 3: , P.-L. Lollini. Perspectives in immunotherapy. Suppl. Tumori, 2: S11-S12, V. Budagian, P. Nanni, P.-L. Lollini, P. Musiani, E. Di Carlo, E. Bulanova, R. Paus & S. Bulfone-Paus. Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein. Scand. J. Immunol. 55: , Retraction in Scand. J. Immunol. 73: 266,

11 K. Scotlandi, C. Maini, M.C. Manara, S. Benini, M. Serra, V. Cerisano, R. Strammiello, N. Baldini, P.-L. Lollini, P. Nanni, G. Nicoletti & P. Picci. Effectiveness of Insulin-like growth factor I receptor antisense strategy against Ewing s sarcoma cells. Cancer Gene Ther., 9: , Ricci, L. Polito, P. Nanni, L. Landuzzi, A. Astolfi, G. Nicoletti, I. Rossi, C. De Giovanni, A. Bolognesi & P.-L. Lollini. HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. J. Immunother., 25: , P.-L. Lollini & G. Forni. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol. Immunother., 51: , P.-L. Lollini, C. De Giovanni, G. Nicoletti, E. Di Carlo, P. Musiani, P. Nanni & G. Forni. Immunoprevention of colorectal cancer: A future possibility? Gastroenterol. Clin. N. Am., 31: , P.-L. Lollini. M.A. Pierotti, C. Gambacorti Passerini, M.R. Bani, G. Zupi, M. Aglietta & A. Albini. 28th meeting of the Italian Cancer Society (SIC). New challenges of molecular oncology. Tumori, 88: 77-81, K. Scotlandi, S. Avnet, S. Benini, M.C. Manara, M. Serra, V. Cerisano, S. Perdichizzi, P.-L. Lollini, C. De Giovanni, L. Landuzzi & P. Picci. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int. J. Cancer, 101: 11-16, M.P. Colombo, P.-L. Lollini, P. Musiani. & G. Forni. Vaccini tumorali, la prospettiva corretta. Bollettino della Società Italiana di Immunologia, Immunologia Clinica e Allergologia, 16 (2): 15-18, P.-L. Lollini. Medicina postgenomica. I Fiori del Maalox, 4: 9-11, 2002 Di Carlo, G. Forni, P.-L. Lollini, M.P. Colombo, A. Modesti & P. Musiani. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood, 97: , Astolfi, P. Nanni, L. Landuzzi, C. Ricci, G. Nicoletti, I. Rossi, P.-L. Lollini & C. De Giovanni. An anti-apoptotic role for NGF receptors in human rhabdomyosarcoma. Eur. J. Cancer, 37: , S.M. Pupa, A.M. Invernizzi, S. Forti, E. Di Carlo, P. Musiani, P. Nanni, P.-L. Lollini, R. Meazza, S. Ferrini & S. Menard. Prevention of spontaneous neuexpressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther., 8: 75-79, De Giovanni, G. Nicoletti, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, E. Di Carlo, P. Musiani, G. Forni, D. Fradelizi, P. Nanni & P.-L. Lollini. Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma. Gene Ther., 8: , L. Cifaldi, E. Quaglino, E. Di Carlo, P. Musiani, M. Spadaro, P.-L. Lollini, S. Wolf, K. Boggio, G. Forni & F. Cavallo. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res., 61: , S. Benini, M.C. Manara, N. Baldini, V. Cerisano, M. Serra, M. Mercuri, P.-L. Lollini, P. Nanni, P. Picci & K. Scotlandi. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin. Cancer. Res., 7: , Astolfi, C. De Giovanni, L. Landuzzi, G. Nicoletti, C. Ricci, S. Croci, L. Scopece, P. Nanni & P.-L. Lollini. Identification of new genes related to the myogenic 11

12 differentiation arrest of human rhabdomyosarcoma cells. Gene, 274: , P. Nanni, G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S.M. Pupa, I. Rossi, M.P. Colombo, C. Ricci, A. Astolfi, P. Musiani, G. Forni & P.-L. Lollini. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med., 194: 1195:1205, Cavallo, E. Di Carlo, E. Quaglino, M. Iezzi, M. Strasly, F. Bussolino, M.P. Colombo, P. Nanni, P.-L. Lollini, P. Musiani & G. Forni. Prevention by delay: Nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice. J. Biol. Regul. Homeost. Agents, , P.-L. Lollini, C. De Giovanni, P. Nanni. Terapia genica. Zanichelli, Bologna, P.-L. Lollini & G. Forni. Progressione tumorale ed immunoprevenzione del cancro. In: F. Dammacco, A. Ferranini & A. Tursi (eds), Allergologia ed immunologia: dalla biologia alla clinica, Monduzzi Editore, Bologna, 2001, pp Atti del Congresso della Società Italiana di Allergologia ed Immunologia Clinica, Bari, 27-30/9/2000. P.-L. Lollini & G. Forni. Terapia genica: modelli animali. In: D. Amadori & S. Grilli (eds.), Oncologia genetica, Poletto Editore, Milano, 2001, pp P.-L. Lollini. Terapia genica dei tumori, stato dell'arte e prospettive. Pathologica, 93: , M.C. Manara, N. Baldini, M. Serra, P.-L. Lollini, C. De Giovanni, M. Vaccari, A. Argnani, S. Benini, D. Maurici, P. Picci & K. Scotlandi. Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone, 26: , S. Ménard, P. Aiello, E. Tagliabue, C Rumio, P.-L. Lollini, M.-I. Colnaghi & A. Balsari. Tamoxifen chemoprevention of hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res., 60: , K. Boggio, E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P.-L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani & G. Forni. Ability of systemic IL-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res., 60: , Ricci, L. Landuzzi, I. Rossi, C. De Giovanni, G. Nicoletti, A. Astolfi, S. Pupa, S. Menard, K. Scotlandi, P. Nanni & P.-L. Lollini. Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by Glial Growth Factor 2 in human rhabdomyosarcoma cells. Int. J. Cancer, 87: 29-36, P. Nanni, S.M. Pupa, G. Nicoletti, C. De Giovanni, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, R. De Vecchi, A.M. Invernizzi, E. Di Carlo, P. Musiani, G. Forni, S. Menard & P.-L. Lollini. p185neu protein is required for tumor and anchorageindependent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer, 87: , M. Giovarelli, P. Capello, G. Forni, T. Salcedo, P.A. Moore, D. W. LeFleur, B. Nardelli, E. Di Carlo, P.-L. Lollini, S. Ruben, S. Ullrich, G. Garotta & P. Musiani. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of antigen presenting cells, lymphocytes and granulocytes. J. Immunol., 164: , K. Scotlandi, S. Benini, M.C. Manara, M. Serra, P. Nanni, P.-L. Lollini, G. Nicoletti, L. Landuzzi, T. Chano, P. Picci & N. Baldini. Murine model for skeletal metastases of Ewing's sarcoma. J. Orthopaed. Res., 18: ,

13 R. Meazza, P.-L. Lollini, P. Nanni, C. De Giovanni, A. Gaggero, A. Comes, M. Cilli, E. Di Carlo, S. Ferrini & P. Musiani. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer, 87: , Forni, P.-L. Lollini, P. Musiani & M.P. Colombo. Immunoprevention of cancer: Is the time ripe? Cancer Res., 60: , S. Rovero, A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P.-L. Lollini, L. Landuzzi, M.P. Colombo, M. Giovarelli, P. Musiani & G. Forni. DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol., 165: , L. Landuzzi, C. De Giovanni, G. Nicoletti, I. Rossi, C. Ricci, A. Astolfi, L. Scopece, K. Scotlandi, M. Serra, G.P. Bagnara, P. Nanni & P.-L. Lollini. The metastatic ability of Ewing's sarcoma cells is modulated by Stem Cell Factor and by its receptor c-kit. Am. J. Pathol., 157: , K. Scotlandi, N. Baldini, V. Cerisano, M.C. Manara, S. Benini, M. Serra, P.-L. Lollini, P. Nanni, G. Nicoletti, G. Bernard, A. Bernard & P. Picci. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res., 60: , F. Cavallo, P. Nanni, P. Dellabona, P.-L. Lollini, G. Casorati & G. Forni. Strategies for enhancing tumor immunogenicity. In: T. Blankenstein (ed.) Gene therapy, Principles and Applications. Birkhauser Verlag, Basel, 1999, pp P. Nanni, G. Forni & P.-L. Lollini. Cytokine gene therapy: Hopes and pitfalls. Annals Oncol., 10: , P.-L. Lollini & G. Forni. Specific and nonspecific immunity in the prevention of spontaneous tumours. Immunol. Today, 20: , S. Benini, N. Baldini, M.C. Manara, T. Chano, M. Serra, S. Rizzi, P.-L. Lollini, P. Picci & K. Scotlandi. Redundancy of autocrine loops in human osteosarcoma. Int. J. Cancer, 80: , Rozera, D. Carlei, P.-L. Lollini, C. De Giovanni, P. Musiani, E. Di Carlo, F. Belardelli & M. Ferrantini. Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response. Am. J. Pathol., 154: , K. Scotlandi, M.C. Manara, M. Serra, S. Benini, D. Maurici, A. Caputo, C. De Giovanni, P.-L. Lollini, P. Nanni, P. Picci, M. Campanacci & N. Baldini. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 18: , M. Giovarelli, P. Musiani, G. Garotta, R. Ebner, E. Di Carlo, Y. Kim, P. Cappello, L. Rigamonti, P. Bernabei, F. Novelli, A. Modesti, A. Coletti, A.K. Ferrie, P.-L. Lollini, S. Ruben, T. Salcedo & G. Forni. A 'stealth effect': adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J. Immunol., 163: , P.-L. Lollini & V. Bronte. The immunotherapy of cancer: understanding mechanisms through animal models. Minerva Biotecnol., 11: , R. De Vecchi, S.M. Pupa, S. Ménard & P.-L. Lollini. Correspondence re: Y. Chen et al., DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors. Cancer Res., 59: , Bevilacqua, R. Giavazzi & P.-L. Lollini. Invasione e metastasi. Pacini Editore, Pisa,

14 R. Giavazzi & P.-L. Lollini. Saggi in vivo. In: G. Bevilacqua, R. Giavazzi & P.-L. Lollini (eds), Invasione e metastasi, Pacini Editore, Pisa, 1999, pp P.-L. Lollini, C. De Giovanni & P. Nanni. Terapia genica in oncologia. In: G. Bevilacqua, R. Giavazzi & P.-L. Lollini (eds), Invasione e metastasi, Pacini Editore, Pisa, 1999, pp P.-L. Lollini, L. Landuzzi, F. Frabetti, I. Rossi, G. Nicoletti, K. Scotlandi, M. Serra, N. Baldini, C. De Giovanni & P. Nanni. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin. Cancer Res., 4: , K. Scotlandi, S. Benini, P. Nanni, P.-L. Lollini, G. Nicoletti, L. Landuzzi, M. Serra, M.C. Manara, P. Picci & N. Baldini. Blockage of Insulin-like Growth Factor-I Receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res., 58: , Rossi, G. Nicoletti, L. Landuzzi, F. Frabetti, C. De Giovanni, P. Nanni, P. Musiani, M. Ferrantini, F. Belardelli & P.-L. Lollini. Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. Clin. Expl. Metastasis, 16: , P. Nanni, C. De Giovanni, G. Nicoletti, L. Landuzzi, I. Rossi, F. Frabetti, M. Giovarelli, G. Forni, F. Cavallo, E. Di Carlo, P. Musiani & P.-L. Lollini. The immune response elicited by mammary adenocarcinoma cells transduced with gamma-interferon and cytosine deaminase genes cures lung metastases by parental cells. Hum. Gene Therapy, 9: , P.-L. Lollini, G. Nicoletti, L. Landuzzi, C. De Giovanni, I. Rossi, E. Di Carlo, P. Musiani, W.J. Muller & P. Nanni. Down regulation of Major Histocompatibility Complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer, 77: , Boggio, G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, P. Bouchard, S. Wolf, A. Modesti, P. Musiani, P.-L. Lollini, M.P. Colombo & G. Forni. Interleukin-12 mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice. J. Exp. Med., 188: , De Giovanni, P. Nanni, A. Sacchi, S. Soddu, I. Manni, G. D'Orazi, S. Bulfone-Paus, T. Pohl, L. Landuzzi, G. Nicoletti, F. Frabetti, I. Rossi & P.-L. Lollini. Wild-type p53-mediated down-modulation of IL-15 and IL-15 receptors in human rhabdomyosarcoma cells. Br. J. Cancer, 78: , Landuzzi, P. Strippoli, C. De Giovanni, G. Nicoletti, I. Rossi, R. Tonelli, F. Frabetti, P. Nanni, G.P. Bagnara & P.-L. Lollini. Production of Stem Cell Factor and expression of c-kit in human rhabdomyosarcoma cells: lack of autocrine growth modulation. Int. J. Cancer, 78: , P. Nanni, I. Rossi, C. De Giovanni, L. Landuzzi, G. Nicoletti, A. Stoppacciaro, M. Parenza, M.P. Colombo & P.-L. Lollini. Interleukin 12 gene therapy of MHCnegative murine melanoma metastases. Cancer Res., 58: , P. Musiani, A. Modesti, M. Giovarelli, F. Cavallo, M.P. Colombo, P.-L. Lollini & G. Forni. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today, 18: 32-36, R. Chiaramonte, S. Fasola, P.-L. Lollini, C. De Giovanni & P. Comi Is mts1 (s100a4) gene involved in the metastatic process modulated by gamma-interferon? Pathobiology, 66: 38-40, P.-L. Lollini, G. Palmieri, C. De Giovanni, L. Landuzzi, G. Nicoletti, I. Rossi, C. Griffoni, F. Frabetti, K. Scotlandi, S. Benini, N. Baldini, A. Santoni & P. Nanni. 14

15 Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma, and Ewing's sarcoma. Int. J. Cancer, 71: , P.-L. Lollini, P. Nanni, C. De Giovanni, G. Nicoletti & L. Landuzzi Re: "Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study" (letter). J. Natl. Cancer Inst., 88: , Scotlandi, M. Serra, M.C. Manara, S. Benini, M. Sarti, D. Maurici, P.-L. Lollini, P. Picci, F. Bertoni & N. Baldini. Immunostaining of the p30/32 (MIC2) antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor Human Pathol, 27: , P. Musiani, A. Allione, A. Modica, P.-L. Lollini, M. Giovarelli, F. Cavallo, F. Belardelli, G. Forni & A. Modesti. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab. Invest., 74: , R. Ferracini, M. Olivero, M.F. Di Renzo, M. Martano, C. De Giovanni, P. Nanni, G. Basso, K. Scotlandi, P.-L. Lollini & P. Comoglio. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcoma. Oncogene, 12: , P. Nanni, C. De Giovanni, L. Landuzzi, G. Nicoletti, F. Frabetti, I. Rossi, F. Cavallo, M. Giovarelli, G. Forni & P.-L. Lollini. Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells. Br. J. Cancer, 74: , De Giovanni, L. Landuzzi, F. Frabetti, G. Nicoletti, C. Griffoni, I. Rossi, M. Mazzotti, L. Scotto, P. Nanni & P.-L. Lollini. Antisense Epidermal Growth Factor- Receptor (EGF-R) transfection impairs proliferative ability of human rhabdomyosarcoma cells. Cancer Res., 56: , K. Scotlandi, S. Benini, M. Sarti, M. Serra, P.-L. Lollini, D. Maurici, P. Picci, M.C. Manara & N. Baldini. Insulin-like Growth Factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res., 56: , Landuzzi, F. Frabetti, I. Rossi, C. Griffoni, C. De Giovanni, G. Nicoletti, P. Nanni, R. Miniero, G. Palmieri, A. Santoni & P.-L. Lollini. Expression of transduced Carcinoembryonic Antigen gene in human rhabdomyosarcoma inhibits metastasis. Cancer Res., 56: , P.-L. Lollini & P. Nanni. Minimal requirements for characterization of cytokine gene-transduced tumor cells: a proposal. J. Natl Cancer Inst, 87: , Dall'Olio, M. Chiricolo, P.-L. Lollini, J.T.Y. Lau. Human colon cancer cell lines permanently expressing alpha2,6-sialylated sugar chains by transfection with rat beta-galactoside alpha2,6-sialyltransferase cdna. Biochem. Biophys. Res. Commun., 211: , De Giovanni, C. Melani, P. Nanni, L. Landuzzi, G. Nicoletti, F. Frabetti, C. Griffoni, M.P. Colombo, P.-L. Lollini. Redundancy of autocrine loops in human rhabdomyosarcoma cells. Induction of differentiation by suramin. Br. J. Cancer, 72: , P.-L. Lollini, C. De Giovanni, L. Landuzzi, G. Nicoletti, F. Frabetti, F. Cavallo, M. Giovarelli, G. Forni, A. Modica, A. Modesti, P. Musiani, P. Nanni. Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer gamma-interferon in the same cell. Efficient MHC expression and inhibition of tumor and metastasis growth. Human Gene Ther., 6: ,

16 P.-L. Lollini, A. D'Errico, C. De Giovanni, L. Landuzzi, F. Frabetti, G. Nicoletti, F. Cavallo, M. Giovarelli, W.F. Grigioni, P. Nanni. Systemic effects of cytokines released by gene-transduced tumor cells: marked hyperplasia induced in small bowel by gamma-interferon transfectants through host's lymphocytes. Int. J. Cancer, 61: , R. Ferracini, M.F. Di Renzo, K. Scotlandi, N. Baldini, M. Olivero, P.-L. Lollini, O. Cremona, M. Campanacci, P.M. Comoglio. The Met/HGF receptor is overexpressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene, 10: , P.-L. Lollini, C. De Giovanni, L. Landuzzi, G. Nicoletti & P. Nanni. Differentiation of rhabdomyosarcoma cells. In: J.B. Griffiths, A. Doyle, D.J. Newell (eds.), "Cell and Tissue Culture: Laboratory Procedures", J. Wiley & Sons, Chichester, 1994, Module 11C:2, pp Allione, M. Consalvo, P. Nanni, P.-L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M.P. Colombo, P. Dellabona, H. Hock, T. Blankenstein, F.M. Rosenthal, B. Gansbacher, M.C. Bosco, T. Musso, L. Gusella & G. Forni. Immunizing and curative potential on replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF-alpha, GM-CSF and IFN-gamma gene or admixed with conventional adjuvants. Cancer Res., 54: , Bontadini, F. Fruet, P.L. Tazzari, P.-L. Lollini, R. Conte. Comparative analysis of six different white cell-reduction filters for packed red cells. Transfusion, 34: , P.-L. Lollini, M.C. Bosco, C. De Giovanni, L. Landuzzi, G. Nicoletti, G. Palmieri, C. Riccardi & P. Nanni. Reduced oncogenicity and enhanced metastatic spread of IFN-gamma transfected tumor cells: therapeutic implications. In: G. Forni, R. Foa', A. Santoni, L. Frati (eds.), Cytokine induced tumor immunogenicity, Academic Press, 1994, pp K. Scotlandi, M. Serra, M.C. Manara, P.-L. Lollini, D. Maurici, D. Del Bufalo & N. Baldini. Pretreatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. Int. J. Cancer, 58: , Ferrantini, M. Giovarelli, A. Modesti, P. Musiani, A. Modica, M. Venditti, E. Peretti, P.-L. Lollini, P. Nanni, G. Forni & F. Belardelli. IFN-alpha1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J. Immunol., 153: , P.-L. Lollini, C. De Giovanni, L. Landuzzi, G. Nicoletti & P. Nanni. Rhabdomyosarcoma cells in nude mice. In: J.B. Griffiths, A. Doyle, D.J. Newell (eds.), "Cell and Tissue Culture: Laboratory Procedure", J. Wiley & Sons, Chichester, 1994, Module 11C:3, pp De Giovanni, G. Nicoletti, M. Sensi, A. Santoni, G. Palmieri, L. Landuzzi, P. Nanni & P.-L. Lollini. H-2Kb and H-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. Int. J. Cancer, 59: , Lauri, C. De Giovanni, T. Biondelli, E. Lalli, L. Landuzzi, A. Facchini, G. Nicoletti, P. Nanni, E. Dejana & P.-L. Lollini. Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumor cells. Br. J. Cancer, 68: ,

17 P.-L. Lollini, M.C. Bosco, F. Cavallo, C. De Giovanni, M. Giovarelli, L. Landuzzi, P. Musiani, A. Modesti, G. Nicoletti, G. Palmieri, A. Santoni, H.A. Young, G. Forni & P. Nanni Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer, 55: , M. Serra, K. Scotlandi, M.C. Manara, D. Maurici, P.-L. Lollini, C. De Giovanni, G. Toffoli & N. Baldini Establishment and characterization of multidrug-resistant human osteosarcoma cell lines Anticancer Res., 13: , De Giovanni, P.-L. Lollini, R. Dolcetti, L. Landuzzi, G. Nicoletti, E. D'Andrea, K. Scotlandi & P. Nanni. Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. Br. J. Cancer, 67: , Andreani, M. Rambaldi, A. Locatelli, F. Andreani, P.-L. Lollini, P. Nanni, R. Bossa & I. Galatulas. Potential antitumor agents. 23.(1) Cytotoxic and differentiating activity of compounds related to hexamethylenebisacetamide. Il Farmaco, 48: , Melchiori, A. Colacci, P.-L. Lollini, C. De Giovanni, S. Carlone, S. Grilli, S. Parodi & A. Albini. Induction of invasive and experimental metastasis potential in BALB/c 3T3 cells by benzo(a)pyrene transformation. Invasion Metastasis, 12: 1-11, Palmieri, S. Morrone, P.-L. Lollini, C. De Giovanni, G. Nicoletti, P. Nanni, L. Frati & A. Santoni. TNF impairs in vivo and in vitro natural killer (NK) susceptibility of B16 melanoma cells. Scand. J. Immunol., 35: , Nicoletti, C. De Giovanni, L. Landuzzi, G. Simone, P. Rocchi, P. Nanni & P.-L. Lollini. Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionizing radiation, N,N-dimethylformamide and their combination. Br. J. Cancer, 65: , Colacci, P. Perocco, M. Vaccari, P. Silingardi, C. Da Via', C. De Giovanni, P.-L. Lollini, P. Nanni, G. Nicoletti, A. Albini, S. Parodi & S. Grilli. In vitro assay of halogenated compounds transforming activity as suitable model for studying multistep carcinogenesis. In: Kanduc D. & Pani. P. (eds.), Carcinogenesis as process, University of Bari, 1992, pp Nanni, L. Landuzzi, G. Nicoletti, C. De Giovanni, M. Giovarelli, E. Lalli, A. Facchini, P.-L. Lollini. Control of H-2 expression in transformed nonhaemopoietic cells by autocrine interferon. Br. J. Cancer, 66: , P.-L. Lollini, L. Landuzzi, G. Nicoletti, C. De Giovanni, M. Giovarelli, E. Lalli, A. Facchini & P. Nanni. Ly-6A/E gene is widely expressed among transformed nonhematopoietic cells. Autocrine modulation by interferon. Anticancer Res., 12: , Amadori, F. Belardelli, F. Cavallo, P. Cornaglia Ferraris, A. De Rossi, G. Doria, G. Forni, M. Forni, R. Giavazzi, C. Jemma, P.-L. Lollini, P. Lusso, D. Mezzanzanica, P. Nanni, G. Parmiani, S. Roncella, G. Scala, M.L. Sensi. A consensus view on the use of immunodeficient mice in immunology and oncology: Mind the mouse! J. Immunol. Res., 4: 1-5, K. Scotlandi, N. Baldini, M. Campanacci, P.-L. Lollini, P. Picci & M. Serra. Induction of HLA class II antigens in osteosarcoma cells by interferons and Tumor Necrosis Factor alfa. Anticancer Res., 12: , Palmieri, S. Morrone, P.-L. Lollini, C. De Giovanni, G. Nicoletti, P. Nanni, L. Frati, A. Santoni. TNF-alpha induces resistance to NK reactivity. J. Chemother., III, Suppl. 3: 38-40,

18 P.-L. Lollini, C. De Giovanni, L. Landuzzi, G. Nicoletti, K. Scotlandi & P. Nanni. Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion Metastasis, 11: , De Giovanni, G. Palmieri, G. Nicoletti, L. Landuzzi, K. Scotlandi, A. Bontadini, P.- L. Tazzari, M. Sensi, A. Santoni, P. Nanni & P.-L. Lollini. Immunological and nonimmunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. Int. J. Cancer, 48: , Colacci, P. Perocco, C. Da Via', P. Silingardi, M. Vaccari, P. Nanni, C. De Giovanni, P.-L. Lollini, G. Nicoletti, A. Albini, S. Parodi, R. Dolcetti, M. Boiocchi & S. Grilli. In vitro cell transformation by halogenated compounds: an in vitro model to study multistep carcinogenesis. In: G. Ragnotti, M. Presta, G. Mazzoleni (eds.), La cancerogenesi come processo, Edi-Ermes, Milano, 1991, pp P.-L. Lollini, C. De Giovanni, L. Landuzzi, G. Nicoletti, P. Nanni & S. Grilli. Cytokines and tumor malignancy: adverse effects revealed by experimental model systems. In: A. Manni, F. Pannuti, G. Robustelli Della Cuna (Eds.), Biological modulators and clinical response in oncology, Edimes, Pavia, 1991, pp Nanni, G. Azzarello, L. Tessarollo, C. De Giovanni, P.-L. Lollini, G. Nicoletti, K. Scotlandi, L. Landuzzi, M. Panozzo, E. D'Andrea, S. Schiaffino & L. Chieco- Bianchi. In vitro differentiation of rhabdomyosarcomas induced by nickel or by Moloney Murine Sarcoma Virus. Br. J. Cancer, 63: , G. Palmieri, S. Morrone, P.-L. Lollini, C. De Giovanni, G. Nicoletti, P. Nanni, L. Frati & A. Santoni. TNF-alpha negatively affects natural killer susceptibility of B16 melanoma. In: Schmidt R.E. (ed.), Natural Killer Cells: Biology and Clinical Applications, Karger, Basel, 1990, pp P.-L. Lollini, C. De Giovanni, G. Nicoletti, A. Bontadini, P.L. Tazzari, L. Landuzzi, K. Scotlandi & P. Nanni. Enhancement of experimental metastatic ability by tumor necrosis factor-alfa alone or in combination with interferon-gamma. Clin. Expl. Metastasis, 8: , P.-L. Lollini, C. De Giovanni, G. Nicoletti, K. Scotlandi, L. Landuzzi & P. Nanni. Modulation by IFN-gamma of the metastatic ability of murine, human, and H-2- transfected tumor cells. Tumori, 75: , De Giovanni, G. Nicoletti, B. Del Re, K. Scotlandi, G. Prodi, P.-L. Lollini & P. Nanni. Tumorigenic and metastatic ability of SV40-transformed BALB/c cell lines and MHC antigens expression. J. Immunogenetics, 16: 45-51, P.-L. Lollini, C. De Giovanni, B. Del Re, L. Landuzzi, G. Nicoletti, G. Prodi, K. Scotlandi & P. Nanni. Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. Cancer Res., 49: , Nanni, C. De Giovanni, G. Nicoletti, B. Del Re, K. Scotlandi & P.-L. Lollini. Human rhabdomyosarcoma cells in nude mice as a model for metastasis and differentiation. Invasion Metastasis, 9: , M. Campanacci, G.P. Bagnara, M. Serra, M. Giovannini, P. Tomasi, S. Pileri, S. Poggi, P.-L. Lollini, P. Picci & G. Paolucci. Giant cell tumor of the bone: a model for the in vitro human osteoclast characterization. Tumori, 75: , De Giovanni, P. Nanni, G. Nicoletti, C. Ceccarelli, K. Scotlandi, L. Landuzzi & P.- L. Lollini. Metastatic ability and differentiative properties of a new cell line of human embryonal rhabdomyosarcoma (CCA). Anticancer Res., 9: , G. Nicoletti, C. De Giovanni, P.-L. Lollini, G.P. Bagnara, K. Scotlandi, L. Landuzzi, B. Del Re, G. Zauli, G. Prodi & P. Nanni. In vivo and in vitro production of 18

19 haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. Eur. J. Cancer Clin. Oncol., 25: , P.-L. Lollini, S. Grilli, C. De Giovanni, G. Nicoletti & P. Nanni. The biological mechanisms of tumor progression. In: D. Amadori, A. Ravaioli, R. Ridolfi (eds.), Strategies in Cancer Medical Therapy: Biological Bases and Clinical Implications, Edimes, Pavia, 1989, pp P.-L. Lollini, C. De Giovanni, B. Del Re, G. Nicoletti, G. Prodi, K. Scotlandi & P. Nanni. Interferon-mediated modulation of metastasis and MHC antigens. In: G. Prodi, L.A. Liotta, P.-L. Lollini, S. Garbisa, S. Gorini, K. Hellmann (eds.), Cancer Metastasis - Biological and Biochemical Mechanisms and Clinical Aspects, Plenum Publishing Co., New York, 1988, pp De Giovanni, P.-L. Lollini, B. Del Re, G. Nicoletti, G. Prodi, K. Scotlandi & P. Nanni Heterogeneity and clonal interactions in the TS/A murine mammary adenocarcinoma. In: G. Prodi, L.A. Liotta, P.-L. Lollini, S. Garbisa, S. Gorini, K. Hellmann (eds.), Cancer Metastasis - Biological and Biochemical Mechanisms and Clinical Aspects, Plenum Publishing Co., New York, 1988, pp Garbisa, C. De Giovanni, G. Biagini, V. Vasi, W.F. Grigioni, A. D'Errico, A.M. Mancini, B. Del Re, P.-L. Lollini, P. Nanni, G. Nicoletti & G. Prodi. Different metastatic aggressiveness by murine TS/A clones: ultrastructure, extracellular glycoproteins and type IV collagenolytic activity. Invasion Metastasis, 8: , G. Nicoletti, P.-L. Lollini, G.P. Bagnara, C. De Giovanni, B. Del Re, L. Bonsi, G. Prodi & P. Nanni. Are colony-stimulating factor-producing cells facilitated in the metastatic process? Anticancer Res., 7: , 1987 De Giovanni, P.-L. Lollini, G. Nicoletti, B. Del Re, K. Scotlandi, G. Prodi & P. Nanni. Growth and metastasis in allogeneic hosts. Lack of H-2 negative or somatic hybrid variant selection. Expl. Clin. Immunogenet., 4: , P.-L. Lollini, C. De Giovanni, B. Del Re, G. Nicoletti, G. Prodi & P. Nanni. Interferon-mediated enhancement of metastasis. Are MHC antigens involved? Clin. Expl. Metastasis, 5: , P.-L. Lollini, C. De Giovanni, S. Garbisa, G. Nicoletti, P. Nanni & G. Prodi. Metastasi. Meccanismi biologici e biochimici ed aspetti clinici. Minuti, 76: 39-46, De Giovanni, P.-L. Lollini, G. Nicoletti, S. Grilli, G. Prodi & P. Nanni. Dexamethasone modulation of in vitro growth pattern and of lung colonization ability in clones of a metastatic BALB/c mammary carcinoma cell line. Clin. Expl. Metastasis, 4: 13-23, P. Nanni, C. De Giovanni, P.-L. Lollini, G. Nicoletti & G. Prodi. Clones with different metastatic capacity and variant selection during metastasis: a problematic relationship. J. Natl. Cancer Inst., 76: 87-93, P. Nanni, S. Schiaffino, C. De Giovanni, G. Nicoletti, G. Prodi, B. Del Re, V. Eusebi, C. Ceccarelli, L. Saggin & P.-L. Lollini. RMZ: A new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin Br. J. Cancer, 54: , P.-L. Lollini, C. De Giovanni, B. Del Re, G. Nicoletti, G. Prodi & P. Nanni. Gli antigeni di istocompatibilita' nella cancerogenesi e nella metastatizzazione. In: "La Cellula Neoplastica", G. Prodi et al. (Eds.), pp , C.E.A., Milano, P.-L. Lollini, M.P. Colombo, C. De Giovanni, G. Nicoletti, G. Parmiani, G. Prodi & P. Nanni. In vivo reexpression of H-2 antigens in B16 melanoma cells. Expl. Clin. Immunogenetics, 2: 14-23,

20 G. Nicoletti, P. Brambilla, C. De Giovanni, P.-L. Lollini, B. Del Re, A. Marocchi, P. Mocarelli, G. Prodi & P. Nanni. Colony-stimulating activity from the new metastatic TS/A cell line and its high- and low-metastatic clonal derivatives. Br. J. Cancer, 52: , P.-L. Lollini, C. De Giovanni, V. Eusebi, G. Nicoletti, G. Prodi, & P. Nanni. Highmetastatic clones selected in vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line. Clin. Expl. Metastasis, 2: , P. Nanni, C. De Giovanni, P.-L. Lollini, G. Nicoletti & G. Prodi. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Expl. Metastasis, 1: , G. Nicoletti, P. Nanni, C. De Giovanni, M.C. Galli, P.-L. Lollini, G. Prodi, M. Gobbi, S. Bartoli & S. Grilli. Evidence of a progestin binding protein in mononuclear cells from peripheral blood of patients with leukaemia or normal donors. J. Exp. Clin. Cancer Res., 4: , De Giovanni, S. Grilli, P.-L. Lollini, G. Nicoletti, G. Prodi & P. Nanni. Inverse relationship between anti-sv40 TASA and anti-h-2 cytotoxic responses. J. Cancer Res. Clin. Oncol., 106: , P. Nanni, M.P. Colombo, C. De Giovanni, P.-L. Lollini, G. Nicoletti, G. Parmiani & G. Prodi. Impaired H-2 expression in B16 melanoma variants. J. Immunogenetics, 10: , P. Nanni, G. Nicoletti, G. Prodi, M.C. Galli, C. De Giovanni, S. Grilli, P.-L. Lollini, M. Gobbi, M. Cavo & S. Tura. Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia. Cancer, 49: , P. Nanni, C. De Giovanni, M.C. Galli, S. Grilli, P.-L. Lollini, G. Nicoletti & G. Prodi. Minor histocompatibility antigens do not enhance BALB/c anti-sv40 TASA response. Br. J. Cancer, 44: , G. Nicoletti, M.C. Galli, C. De Giovanni, S. Grilli, P. Nanni, P.-L. Lollini, P. Bassi, S. Bartoli & G. Prodi. The simultaneous occurrence of cytoplasmic receptors for steroid hormones in normal and pathological female breast tissues. IRCS Med. Sci., 9: , P. Nanni, G. Prodi, C. De Giovanni, M.C. Galli, G. Nicoletti, P.-L. Lollini & S. Grilli. Manipolazione antigenica della cellula neoplastica. In: "Apporto della Ricerca di Base al Controllo della Crescita Neoplastica, Idelson, Napoli, 1981, vol I, pp P. Nanni, C. De Giovanni, M.C. Galli, G. Nicoletti, P.-L. Lollini, M. Gobbi, S. Bartoli & S. Grilli. Glucocorticoid binding protein occurrence and glucocorticoid sensitivity in cells from human acute lymphoblastic leukaemia. IRCS Med. Sci., 8: 624, P. Nanni, C. De Giovanni, M.C. Galli, G. Nicoletti, P.-L. Lollini, M. Gobbi, S. Bartoli & S. Grilli. Glucocorticoid binding protein determination by different tracers in human leukaemic cells. IRCS Med. Sci., 8: ,

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression

More information

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer

More information

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

The Need for a PARP in vivo Pharmacodynamic Assay

The Need for a PARP in vivo Pharmacodynamic Assay The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235

More information

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

Microbiology AN INTRODUCTION EIGHTH EDITION

Microbiology AN INTRODUCTION EIGHTH EDITION TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein

More information

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015 The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

More information

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology: Technology, Products, Market and Service Opportunities Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Publikationsliste Claudia Götz

Publikationsliste Claudia Götz Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography

More information

FARMACI PERSONALIZZATI PER

FARMACI PERSONALIZZATI PER ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI

More information

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D.

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D. Pier Paolo Di Fiore M.D. Ph.D. Curriculum Vitae Education 1981 - M.D., summa cum laude, University of Naples, 2nd Medical School, Naples, Italy 1984 - Board in Oncology, summa cum laude, University of

More information

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae Ariela Benigni Biol.Sci.D., Ph.D. Curriculum Vitae Personal Data Name: Date and place of birth: Citizenship: E-mail: Ariela Benigni December 16, 1955 - Bergamo, Italy Italian ariela.benigni@marionegri.it

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function: Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic

More information

A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression

A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression September 27, 2011 James A. Joyce Chairman & CEO, Aethlon Medical, Inc jj@aethlonmedical.com Last week, we introduced HER2osome as a

More information

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects

More information

Contents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer

Contents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer Contents Introduction: biology and medicine, two separated compartments What we need to know: - boring basics in DNA/RNA structure and overview of particular aspects of molecular biology techniques - How

More information

Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University

Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Changing Paradigms in Cancer Treatment Potential Uses of Biomarkers Adverse event

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

INTERNATIONAL COURSE:

INTERNATIONAL COURSE: INTERNATIONAL COURSE: Novel mechanisms of signal transduction involved in cancer chemoresistance - Focus on IGF signaling integration and cross-talk. University Campus S Venuta - Catanzaro, Italy Lecture

More information

Chapter 17A: Adaptive Immunity Part I

Chapter 17A: Adaptive Immunity Part I Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

Immunotherapy Concept Turned Reality

Immunotherapy Concept Turned Reality Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a

More information

Autoimmunity and immunemediated. FOCiS. Lecture outline

Autoimmunity and immunemediated. FOCiS. Lecture outline 1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

Interferon Fundamentals 2014

Interferon Fundamentals 2014 From Molecular Mechanisms to Human Diseases Rome, Auditorium Pocchiari Istituto Superiore di Sanità Over the last two decades, we have witnessed a tremendous progress in understanding the mechanisms by

More information

Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1

Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany

More information

Ph.D. in Molecular Medicine

Ph.D. in Molecular Medicine Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to

More information

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

More information

Curriculum Vitae of Luca Gianni

Curriculum Vitae of Luca Gianni Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities

More information

Micro 204 Tumor Immunology.

Micro 204 Tumor Immunology. Micro 204 Tumor Immunology Lewis.Lanier@ucsf.edu Immunological Surveillance Ehrlich, Burnet & Thomas Paul Ehrlich (1909) Concept of cancer immunosurveillance. Predicted that cancer would occur at incredible

More information

VIRUSES AND CANCER. Michael Lea

VIRUSES AND CANCER. Michael Lea VIRUSES AND CANCER 2012 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review

More information

Rilevanza dell innovazione tecnologica per la

Rilevanza dell innovazione tecnologica per la Rilevanza dell innovazione tecnologica per la ricerca traslazionale e la terapia in oncologia Ruggero De Maria Dipartimento di Ematologia Oncologia e Medicina Molecolare, Istituto Superiore di Sanità Translational

More information

CONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294

CONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294 AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at

More information

A disease of populations of cells that live, divide, invade and spread without regard to normal limits

A disease of populations of cells that live, divide, invade and spread without regard to normal limits 1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without

More information

Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi

Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.

More information

Name (print) Name (signature) Period. (Total 30 points)

Name (print) Name (signature) Period. (Total 30 points) AP Biology Worksheet Chapter 43 The Immune System Lambdin April 4, 2011 Due Date: Thurs. April 7, 2011 You may use the following: Text Notes Power point Internet One other person in class "On my honor,

More information

Making the switch to a safer CAR-T cell therapy

Making the switch to a safer CAR-T cell therapy Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction

More information

basse dosi in radioterapia

basse dosi in radioterapia Workshop Interdisciplinare radiazioni: biologia, clinica, ambiente e protezione Centro Ricerche Casaccia ENEA Roma, 14 maggio 2009 basse dosi in radioterapia Alessio G. Morganti 1,2,3, Mariangela Massaccesi

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

4.1 3T12 and 312 are immortalized cell lines with transforming potential:

4.1 3T12 and 312 are immortalized cell lines with transforming potential: DISCUSSION CHAPTER 4 4.1 3T12 and 312 are immortalized cell lines with transforming potential: Transformation of a normal cell with finite number of divisions into a tumorigenic cell of potentially infinite

More information

Activation and effector functions of HMI

Activation and effector functions of HMI Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ

More information

Immune Checkpoint Blockade in Acute Myeloid Leukemia. Kinsey McCormick Hematology Fellow s Conference January 10, 2014

Immune Checkpoint Blockade in Acute Myeloid Leukemia. Kinsey McCormick Hematology Fellow s Conference January 10, 2014 Immune Checkpoint Blockade in Acute Myeloid Leukemia Kinsey McCormick Hematology Fellow s Conference January 10, 2014 Overview Overview of immune checkpoints Immune checkpoints as mechanism of immune evasion

More information

CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD

CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD NAME Roberto Giacomelli TITLE Full Professor of Rheumatology, University of L Aquila, School of Medicine, L Aquila, Italy NATIONALITY Italian ADDRESS Permanent:

More information

Evaluation of the role of gene polymorphisms in anticancer drug efficacy using in vitro models

Evaluation of the role of gene polymorphisms in anticancer drug efficacy using in vitro models Group members and Contact details Jacques Robert graduated in medicine from the University of Strasbourg in 1974 and received hi Research projects: The objectives of our group are: (1) to identify preclinical

More information

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic

More information

Europass Curriculum Vitae

Europass Curriculum Vitae Europass Curriculum Vitae Personal information First name(s) / Surname(s) Address(es) Department of Molecular Immunology, Viale Regina Elena 329 00161-Rome Italy Telephone(s) +39 06 49970517/ +39 06 49970586

More information

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis. Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)

More information

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Appendix One. HER2-positive early breast cancer, its treatment and prognosis Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf

More information

E UROPEAN CURRICULUM VITAE FORMAT

E UROPEAN CURRICULUM VITAE FORMAT E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Address VALENTINA GUARNERI University of Padova Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche Istituto Oncologico Veneto

More information

A disease and antibody biology approach to antibody drug discovery

A disease and antibody biology approach to antibody drug discovery A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!

More information

Cellular, Molecular, and Biochemical Targets in Breast Cancer

Cellular, Molecular, and Biochemical Targets in Breast Cancer Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm

More information

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio 10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Immune Therapy for Pancreatic Cancer

Immune Therapy for Pancreatic Cancer Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

PROGRAMMA SCIENTIFICO

PROGRAMMA SCIENTIFICO PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY

More information

B Cells and Antibodies

B Cells and Antibodies B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production

More information

Basic Overview of Preclinical Toxicology Animal Models

Basic Overview of Preclinical Toxicology Animal Models Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background

More information

Luca Romagnoli, Ph.D. Business Development Manager

Luca Romagnoli, Ph.D. Business Development Manager Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies

More information

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425

More information

Enhancing Anti-Tumor Activity of Checkpoint Inhibition

Enhancing Anti-Tumor Activity of Checkpoint Inhibition Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

Chapter 43: The Immune System

Chapter 43: The Immune System Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2

More information

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion. Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1)

Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1) Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1) Verónica Cánovas, PhD Student Laboratory of Cell Signalling and Cancer Progression, Dra. Rosanna Paciucci

More information

Dendritic Cells: A Basic Review *last updated May 2003

Dendritic Cells: A Basic Review *last updated May 2003 *last updated May 2003 Prepared by: Eric Wieder, PhD MD Anderson Cancer Center Houston, TX USA What is a dendritic cell? Dendritic cells are antigen-presenting cells (APCs) which play a critical role in

More information

Introduction to Pathology and Diagnostic Medicine

Introduction to Pathology and Diagnostic Medicine Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

Miquel Àngel Seguí Palmer

Miquel Àngel Seguí Palmer Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.

OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Title of the poster Authors Sheffield Cancer Research Centre University of Sheffield OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Dr Penelope Ottewell Background

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

Cytotoxic and Biotherapies Credentialing Programme Module 2

Cytotoxic and Biotherapies Credentialing Programme Module 2 Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal

More information

Cell signalling in the immune system: receptors, coreceptors and cytokines (from basic to clinic) Genoa (Italy), June 19-20, 2000

Cell signalling in the immune system: receptors, coreceptors and cytokines (from basic to clinic) Genoa (Italy), June 19-20, 2000 Cell signalling in the immune system: receptors, coreceptors and cytokines (from basic to clinic) Genoa (Italy), June 19-20, 2000 Sala del Maggior Consiglio - Palazzo Ducale Piazza Matteotti, 5 Monday,

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

International Symposium on Malignant Mesothelioma 2011 -- curemeso.org

International Symposium on Malignant Mesothelioma 2011 -- curemeso.org Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not

More information

Bioinformatics for cancer immunology and immunotherapy

Bioinformatics for cancer immunology and immunotherapy Bioinformatics for cancer immunology and immunotherapy Zlatko Trajanoski Biocenter, Division for Bioinformatics Innsbruck Medical University Innrain 80, 6020 Innsbruck, Austria Email: zlatko.trajanoski@i-med.ac.at

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

Metastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months.

Metastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months. TACT-2C Trial A phase II randomized, open-label study evaluating the addiction of trastuzumabto (nabtm)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with

More information

Cancer and the immune system: can we beat cancer at its own game?

Cancer and the immune system: can we beat cancer at its own game? Cancer and the immune system: can we beat cancer at its own game? Andrew R. Haas, MD, PhD Assistant Professor of Medicine University of Pennsylvania Medical Center Philadelphia, Pa Why can t immune

More information

An Introduction To Immunotherapy And The Promise Of Tissue Phenomics

An Introduction To Immunotherapy And The Promise Of Tissue Phenomics An Introduction To Immunotherapy And The Promise Of Tissue Phenomics INSIDE: n The Potential of Immunotherapy n Towards an Understanding of Immunotherapy n Current Approaches to Immunotherapy n The Immunotherapy

More information

On the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma

On the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma On the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma Uber die Entstehung von multinuklearen Reed-Sternberg Riesenzellen und die Rolle von CD4 T-Zellen

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

in silico hematology

in silico hematology in silico hematology Application of mathematical modeling to predict the outcome of leukemia treatment by Ingmar Glauche and Ingo Röder Chronic Myeloid Leukemia (CML) accounts for about 20 % of all leukemias

More information

Core Topic 2. The immune system and how vaccines work

Core Topic 2. The immune system and how vaccines work Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain

More information

Bottle-neck Problems of Current Human Cancer Therapy

Bottle-neck Problems of Current Human Cancer Therapy International Conference on Human Cell, Tissue-based Products and Tissue Banks, Oct. 13-14,Taipei, Taiwan Autologous Dendritic Cell-based Immunotherapy of Glioblastoma Multiforme: Post-Phase-I Clinical

More information

Lung Cancer Research: From Prevention to Cure!

Lung Cancer Research: From Prevention to Cure! Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology

More information

RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE. Graduatoria e Finanziamento

RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE. Graduatoria e Finanziamento Direzione Generale Ricerca Scientifica e Tecnologica RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE Graduatoria e Finanziamento Ministero della Salute Direzione Generale Ricerca Scientifica e Tecnologica

More information

An Introduction to Stem Cell Biology. Michael L. Shelanski, MD,PhD Professor of Pathology and Cell Biology Columbia University

An Introduction to Stem Cell Biology. Michael L. Shelanski, MD,PhD Professor of Pathology and Cell Biology Columbia University An Introduction to Stem Cell Biology Michael L. Shelanski, MD,PhD Professor of Pathology and Cell Biology Columbia University Figures adapted from ISSCR. Presentations of Drs. Martin Pera (Monash University),

More information

CCR Biology - Chapter 9 Practice Test - Summer 2012

CCR Biology - Chapter 9 Practice Test - Summer 2012 Name: Class: Date: CCR Biology - Chapter 9 Practice Test - Summer 2012 Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Genetic engineering is possible

More information